ABSTRACT
The World Health Organization (WHO) was notified of an infection in the respiratory tract of pneumonia patients in Wuhan, Hubei Province, China in December 2019, which was later identified as a newly discovered coronavirus (nCoV). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped virus with a lengthy RNA genome encased in a protective capsid. The signal peptide (amino acids 1–13) found at the N-terminus, the S1 subunit (14–685 residues) and the S2 subunit (686–1273 residues) make up the entire length of the SARS-CoV-2 S protein, which is 1273 amino acids long. The binding of the S glycoprotein to the receptor allows SARS-CoV-2 to enter the host cell. Among the potential therapeutic targets in the life cycle of viruses, viral attachment and entrance are of special interest. Small peptides could be an alternative method for SARS-CoV-2 infectivity, as peptide blockers are very target specific.
